Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OFSET: Adjuvant Chemotherapy Plus Ovarian Function Suppression and Endocrine Therapy vs Ovarian Function Suppression and Endocrine Therapy Alone
jRCT1031260034Phase 3Recruiting
- Sponsor
- NRG Oncology
- Start
- Apr 2026
- Modality
- Small Molecules, Peptides
01
Overview
Phase 3, randomised trial of goserelin, leuprolide, triptorelin and adjuvant chemotherapy in breast cancer (2 arms), sponsored by NRG Oncology. Primary endpoint: Invasive breast cancer-free survival. Started Apr 2026; status: recruiting.
02
Drugs
goserelinleuprolidetriptorelinadjuvant chemotherapy
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT1031260034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031260034.